Annual report pursuant to Section 13 and 15(d)

Note 24 - Supplemental Disclosure for Statements of Cash Flows (Details Textual)

v3.8.0.1
Note 24 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended
Jan. 31, 2017
Mar. 31, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Nov. 30, 2017
Mar. 31, 2017
Mar. 03, 2017
Interest Paid     $ 7,400,000 $ 5,500,000 $ 4,600,000      
Stock Issued During Period, Shares, Employee Benefit Plan     105,308 67,002 68,157      
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution     $ 53,707 $ 120,800 $ 117,099      
Prepaid Insurance       348,000   $ 396,000    
Notes Payable End of Term Fees         1,000,000      
Reclassification of Funds Invested $ 200,000   200,000          
Derivative Liability     63,000 63,000        
Preferred Stock Dividends and Other Adjustments     $ 46,000      
Macrophage Therapeutics [Member] | Convertible Preferred Stock [Member]                
Preferred Stock Dividends and Other Adjustments   $ 46,000            
Series NN Warrants [Member] | UCSD [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights     1,000,000       1,000,000 1,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value     $ 334,000          
Capital Royalty Group, Term Loan [Member]                
Payments to Collection of Collateral on Claims of Default       778,000        
Payments to Prepayment Premium on Claims of Default       $ 2,100,000        
Note Payable to IPFS [Member]                
Debt Instrument, Interest Rate, Stated Percentage       8.99%   4.00%